Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: Influence of nanoparticle size and administration route.
Jeannot V, Mazzaferro S, Lavaud J, Vanwonterghem L, Henry M, Arboléas M, Vollaire J, Josserand V, Coll JL, Lecommandoux S, Schatz C, Hurbin A. Jeannot V, et al. Among authors: vanwonterghem l. Nanomedicine. 2016 May;12(4):921-932. doi: 10.1016/j.nano.2015.11.018. Epub 2015 Dec 24. Nanomedicine. 2016. PMID: 26724540 Free article.
Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.
Gilson P, Josa-Prado F, Beauvineau C, Naud-Martin D, Vanwonterghem L, Mahuteau-Betzer F, Moreno A, Falson P, Lafanechère L, Frachet V, Coll JL, Fernando Díaz J, Hurbin A, Busser B. Gilson P, et al. Among authors: vanwonterghem l. Sci Rep. 2017 Aug 31;7(1):10209. doi: 10.1038/s41598-017-09491-9. Sci Rep. 2017. PMID: 28860487 Free PMC article.
The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo.
Gilson P, Couvet M, Vanwonterghem L, Henry M, Vollaire J, Baulin V, Werner M, Orlowska A, Josserand V, Mahuteau-Betzer F, Lafanechère L, Coll JL, Busser B, Hurbin A. Gilson P, et al. Among authors: vanwonterghem l. Biochem Pharmacol. 2019 Feb;160:1-13. doi: 10.1016/j.bcp.2018.12.004. Epub 2018 Dec 7. Biochem Pharmacol. 2019. PMID: 30529691
Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
Bouclier C, Simon M, Laconde G, Pellerano M, Diot S, Lantuejoul S, Busser B, Vanwonterghem L, Vollaire J, Josserand V, Legrand B, Coll JL, Amblard M, Hurbin A, Morris MC. Bouclier C, et al. Among authors: vanwonterghem l. Theranostics. 2020 Jan 12;10(5):2008-2028. doi: 10.7150/thno.40971. eCollection 2020. Theranostics. 2020. PMID: 32104498 Free PMC article.
12 results